We are live on ! Find out more
3C

325 Capital Portfolio holdings

AUM $274M
1-Year Est. Return 49.96%
This Fund
S&P 500
This Quarter Est. Return
+14.37%
1 Year Est. Return
+49.96%
3 Year Est. Return
+158.78%
5 Year Est. Return
10 Year Est. Return
AUM
$217M
AUM Growth
+$14.7M
Cap. Flow
-$5.79M
Cap. Flow %
-2.67%
Top 10 Hldgs %
94.67%
Holding
13
New
Increased
1
Reduced
Closed
1

Top Buys

Rank Stock Value
1
LFCR icon
Lifecore Biomedical
LFCR
+$956K

Top Sells

Rank Stock Value
1
DSKE
Daseke, Inc. Common Stock
DSKE
+$6.75M

Sector Composition

Rank Sector Weight
1 Industrials 37.88%
2 Healthcare 24.87%
3 Technology 10.4%
4 Consumer Staples 8.41%
5 Consumer Discretionary 5.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
BLBD icon
1
Blue Bird Corp
BLBD
$2.41B
$44.6M 20.61%
1,164,207
ATRO icon
2
Astronics
ATRO
$3.45B
$31.2M 14.39%
1,963,426
SGOV icon
3
iShares 0-3 Month Treasury Bond ETF
SGOV
$98.6B
$28.6M 13.21%
284,137
ASTH icon
4
Astrana Health
ASTH
$2B
$24.9M 11.49%
592,810
BTMD icon
5
Biote Corp
BTMD
$69.2M
$21.8M 10.09%
3,766,666
APEI icon
6
American Public Education
APEI
$875M
$18.2M 8.41%
1,283,284
MPAA icon
7
Motorcar Parts of America
MPAA
$261M
$11.3M 5.22%
1,405,057
IDCC icon
8
InterDigital
IDCC
$6.68B
$10M 4.62%
93,966
COHU icon
9
Cohu
COHU
$2.39B
$7.23M 3.34%
216,823
LFCR icon
10
Lifecore Biomedical
LFCR
$162M
$7.12M 3.29%
1,340,598
+133,629
+11% +$956K
HTLD icon
11
Heartland Express
HTLD
$1.11B
$6.25M 2.89%
523,404
TACT icon
12
Transact Technologies
TACT
$51.7M
$5.3M 2.45%
1,011,789
DSKE
13
DELISTED
Daseke, Inc. Common Stock
DSKE
-833,045
Closed -$6.75M

Similar funds

325 Capital's Q1 2024 Portfolio in Review

As of Q1 2024, 325 Capital held 13 positions worth $217M, up 7.3% from $202M the previous quarter. Its ten largest holdings account for 95% of the portfolio.

325 Capital's Q1 2024 filing shows 1 increased and 1 closed positions. The largest sale was Daseke, Inc. Common Stock, an estimated $6.75M.

By sector, the portfolio is most concentrated in Industrials at 38% of assets, up from 33% a quarter earlier, followed by Healthcare and Technology.

  • 325 Capital added most to Lifecore Biomedical in Q1 2024, an estimated $956K increase.
  • 325 Capital fully exited Daseke, Inc. Common Stock in Q1 2024, selling an estimated $6.75M.
  • 325 Capital's ten largest holdings make up 95% of its $217M portfolio in Q1 2024.
  • 325 Capital opened 0 new positions and closed 1 in Q1 2024.
  • 325 Capital's portfolio value rose 7.3% quarter-over-quarter to $217M.

Based on 325 Capital's 13F filing for Q1 2024, filed 15 May 2024.